A Phase 3b, Open-label Study to Evaluate the Non-inferiority of the Immune Response and to Evaluate the Safety of the RSVPreF3 OA Investigational Vaccine in Adults 18-49 Years of Age at Increased Risk for Respiratory Syncytial Virus Disease, Compared to Older Adults ≥60 Years of Age
Latest Information Update: 09 Apr 2025
At a glance
- Drugs Respiratory syncytial virus vaccine adjuvanted (Primary)
- Indications Respiratory syncytial virus infections
- Focus Pharmacodynamics
- Sponsors GSK
- 03 Apr 2025 Status changed from active, no longer recruiting to completed.
- 24 Feb 2025 Planned End Date changed from 28 Apr 2025 to 14 Apr 2025.
- 24 Oct 2024 According to GSK media release, data from the study will be will be presented at upcoming medical conferences and submitted for peer-reviewed publication. The final data will also be submitted to the US Food and Drug Administration (FDA) and other regulators to support potential label updates.